Please try another search
For the fiscal year ended 30 November 2016, T&C Medical Science Inc revenues decreased 4% to Y367.6M. Net loss applicable to common stockholders decreased 80% to Y239.8M. Revenues reflect ETF Related Business segment decrease of 96% to Y3.6M, Financial Advisory Business segment decrease of 39% to Y2.3M, Northern America (Region) segment decrease of 96% to Y3.6M, Other segment decrease of 65% to Y11.1M.
Period Ending: | Nov 30, 2016 | Aug 31, 2016 | May 31, 2016 | Feb 29, 2016 |
---|---|---|---|---|
Total Revenue | 157.44 | 54.56 | 69.31 | 86.34 |
Gross Profit | 28.39 | -6.64 | 8.58 | 23.69 |
Operating Income | -58.39 | -207.56 | -100.05 | -136.41 |
Net Income | 231.98 | -259.89 | -138.99 | -72.89 |
Period Ending: | Nov 30, 2016 | Aug 31, 2016 | May 31, 2016 | Feb 29, 2016 |
---|---|---|---|---|
Total Assets | 961.96 | 441.56 | 313.07 | 402.58 |
Total Liabilities | 1284.54 | 1051.48 | 1043.61 | 1014.31 |
Total Equity | -322.58 | -609.92 | -730.54 | -611.73 |
Period Ending: | Nov 30, 2016 | Aug 31, 2016 | May 31, 2016 | Feb 29, 2016 |
---|---|---|---|---|
Period Length: | 12 Months | 0 Months | 6 Months | 0 Months |
Cash From Operating Activities | -411.64 | -287.68 | ||
Cash From Investing Activities | -198.92 | 92.58 | ||
Cash From Financing Activities | 778.21 | 126.8 | ||
Net Change in Cash | 220.18 | -7.73 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review